Advancements in Natural Product‐Based Ischemic Stroke Treatment: Mechanisms, Key Compounds, and Drug Delivery Systems
Drug Development Research · 2026-11 · 87 (7)
DOI: 10.1002/ddr.70397 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 29.10.2026. Verfasst von Nan Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education+Traditional Chinese medicine (TCM) biological genetics (Heilongjian…. Hauptthemen laut MEDLINE: Biological Products, Ischemic Stroke, Drug Delivery Systems, Neuroprotective Agents. Die Arbeit nennt 158 Literaturangaben. Gefördert von: Foundations of the National Natural Science Foundation of China Youth Science Fund Project, Heilongjiang Province Natural Science Foundation Team Project, Heilongjiang Chunyan Innovation Team Program.
Themen: Schlaganfall
Abstract (Originalsprache)
Ischemic stroke (IS) remains the leading global cause of permanent neurological disability and mortality. Narrow therapeutic time windows and elevated hemorrhagic transformation risks restrict conventional clinical interventions, including intravenous thrombolysis and mechanical thrombectomy. Single‐target neuroprotective agents fail to sustain long‐term neurological functional recovery, resulting in unsatisfactory clinical outcomes. Natural products (NPs) derived from traditional Chinese medicine exert protective effects against cerebral ischemia via multiple pathways. However, their poor blood–brain barrier (BBB) permeability, low aqueous solubility, and inadequate in vivo bioavailability greatly hinder clinical translational application. This review systematically summarizes the pathological mechanisms of natural monomers for the treatment of ischemic stroke and four types of brain‐targeted nanocarriers over the past decade. We reconstructed the pathological cascades of cerebral ischemia across the acute, subacute, and chronic repair phases, and critically discussed the inherent limitations of the middle cerebral artery occlusion (MCAO) model and existing monomer‐based preclinical studies. This work provides systematic structure‐activity relationship evidence and insights into nano‐delivery strategies for the development of natural product‐based anti‐stroke therapeutics. We also propose future research directions, such as staged, sequential administration, precise multi‐omics intervention, and standardized nanoformulation development, to accelerate the clinical translation of bioactive ingredients derived from traditional Chinese medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education+Traditional Chinese medicine (TCM) biological genetics (Heilongjiang province double first-class construction interdiscipline), Heilongji…
ORCID-Profile: Nan Yang, Mengmeng Li, Min Wang, Xinyuan Li, Hanya Dong, Junhan Yao, Yan Sun, Juan Pan, Siyi Wang, Jiatong Wu, Gangtao Bu, Haixue Kuang, Yan Liu
Förderung
- Foundations of the National Natural Science Foundation of China Youth Science Fund Project
- Heilongjiang Province Natural Science Foundation Team Project
- Heilongjiang Chunyan Innovation Team Program
- Heilongjiang province double first-class construction interdiscipline
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Zitieren
APA
Yang, N., Li, M., Wang, M., Li, X., Dong, H., Yao, J., Sun, Y., Pan, J., Wang, S., Wu, J., Bu, G., Kuang, H., & Liu, Y. (2026). Advancements in Natural Product‐Based Ischemic Stroke Treatment: Mechanisms, Key Compounds, and Drug Delivery Systems. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70397
Vancouver
Yang N, Li M, Wang M, Li X, Dong H, Yao J, et al. Advancements in Natural Product‐Based Ischemic Stroke Treatment: Mechanisms, Key Compounds, and Drug Delivery Systems. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70397
BibTeX
@article{Yang2026,
author = {Yang, Nan and Li, Mengmeng and Wang, Min and Li, Xinyuan and Dong, Hanya and Yao, Junhan and Sun, Yan and Pan, Juan and Wang, Siyi and Wu, Jiatong and Bu, Gangtao and Kuang, Haixue and Liu, Yan},
title = {Advancements in Natural Product‐Based Ischemic Stroke Treatment: Mechanisms, Key Compounds, and Drug Delivery Systems},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {7},
doi = {10.1002/ddr.70397}
}
EUVIMED